David is currently the Chief Operating Officer of Rgenix, Inc., a cancer therapeutics company developing first in class drugs, where he co-leads the company’s financial, corporate development, and drug development activities. Prior to Rgenix, he was a venture capitalist at OrbiMed Advisors, the world’s largest private healthcare dedicated investment firm. There, he invested in leading private and public companies developing therapeutics for life threatening and debilitating disorders, returning over $200 million and generating a 3X return multiple. He was the founding investor of Good Start Genetics, a reproductive health diagnostics company. Previously, David was a co-founder, EVP, and Director of Potentia Pharmaceuticals, and its spin-off company Apellis, which collectively have raised over $100 million. Apellis’ lead complement inhibitor is in clinical trials for the treatment of age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and chronic obstructive pulmonary disease. David has an MBA from Harvard Business School, and a BA, cum laude, from Harvard College. David sits on the Rockefeller University Advisory Council.